Myeloma Bone Disease: Update on Pathogenesis and Novel Treatment Strategies

• Main Authors: Sonia Vallet, Julia-Marie Filzmoser, Martin Pecherstorfer, Klaus Podar
• Format: Article
• Language: English
• Published: MDPI AG 2018-10-01
• Series: Pharmaceutics
• Subjects: multiple myeloma; osteolytic bone disease; denosumab; bisphosphonates; Wnt inhibitors
• Online Access: https://www.mdpi.com/1999-4923/10/4/202

Bone disease, including osteolytic lesions and/or osteoporosis, is a common feature of multiple myeloma (MM). The consequences of skeletal involvement are severe pain, spinal cord compressions, and bone fractures, which have a dramatic impact on patients’ quality of life and, ultimately, survival. During the past few years, several landmark studies significantly enhanced our insight into MM bone disease (MBD) by identifying molecular mechanisms leading to increased bone resorption due to osteoclast activation, and decreased bone formation by osteoblast inhibition. Bisphosphonates were the mainstay to prevent skeletal-related events in MM for almost two decades. Excitingly, the most recent approval of the receptor activator of NF-kappa B ligand (RANKL) inhibitor, denosumab, expanded treatment options for MBD, for patients with compromised renal function, in particular. In addition, several other bone-targeting agents, including bone anabolic drugs, are currently in preclinical and early clinical assessment. This review summarizes our up-to-date knowledge on the pathogenesis of MBD and discusses novel state-of-the-art treatment strategies that are likely to enter clinical practice in the near future.